STAT+: Pharmalittle: ADC backs off accelerated approval after FDA demands confirmatory trial; explaining the Supreme Court’s split on drug-patent cases

ADC Therapeutics will not seek accelerated approval of its Hodgkin lymphoma drug because the FDA will not review it unless a confirmatory trial is “well underway."

Click to view original post